BAT's 7.9% EPS Lift Still Isn't Enough: Why the Stock Still Looks Too Rich

BAT's turnaround is real, but the stock already reflects much of it

The debate around BAT is no longer whether the turnaround is real. It is. First-half adjusted EPS growth was 7.9%, management raised its full-year outlook to the middle of its 5–8% target range, and the equity is trading at 4,669 GBp, already near the top of its 3,733 to 4,962 GBp 52-week range. The key question now is not whether BAT is improving, but whether the stock is still cheap after that improvement has largely been announced.

That matters because a turnaround near the top of its range leaves less room for error. A few strong quarters can improve sentiment quickly, but they do not automatically create fresh upside at a rich price.

Price is now the deciding factor

The old fear around BAT was structural decline: falling smoked-tobacco volumes, heavy investment in alternatives, and a legacy business that had to fund the transition. That risk is still there, but it is no longer purely theoretical. The bigger risk for investors now is paying near-full price for a story that still requires several more quarters of solid execution.

BAT's operating proof is driving the re-rating

The market is no longer paying for a promise alone. It is responding to evidence that BAT's transformation is reaching meaningful scale.

What bulls are paying for

Investors are starting to see the transformation convert into tangible numbers. Smokeless products now 19.8% of Group revenue, New Categories revenue grew 18.0%, and Modern Oral achieved 39.2% volume share in our top markets. In the U.S., New Categories revenue grew 58.1%. That is the kind of operating proof that can change how the market views a company: less like a pure decline story, more like a tobacco group building replacement growth.

Bulls are also focusing on consumers of Smokeless products reaching 35 million and on Modern Oral's leadership position. That is reasonable. But strong early-scale metrics are not the same as fully proven long-term economics.

Why revenue growth still has to earn a higher valuation

The missing piece is not demand; it is how profitable that growth becomes over time. BAT now expects mid-teens new-category annual revenue growth, and management has highlighted improving U.S. vapour momentum as well. But New Categories contribution margin up 3.3 ppts to 13.8% still suggests the segment is early relative to the weight investors are giving it.

At the same time, combustibles revenue up 2.1% continues to help fund the shift. That is a support, not a substitute. The business is clearly recovering, but the valuation case still depends on whether the new categories can keep maturing without the legacy smoked base weakening too quickly.

Better business performance does not guarantee a better stock

A better business can still be a worse stock if the price already assumes the best version of the transition.

Business progress is real. Valuation is doing more of the work.

At 4,669 GBp, BAT is already near the top of its 52-week range. That means the market is no longer giving the company much benefit of the doubt. It is assuming the transition keeps working, replacement products scale on time, and the smoked-tobacco base stays financially useful long enough for the new engine to matter.

When too many positive assumptions are already in the stock, "good progress" is no longer enough by itself. That helps explain the tension in the setup: investors can believe BAT is transforming successfully and still think the shares are expensive, especially while the company faces the terminal decline of traditional cigarettes.

Morningstar's approach makes that point clearly. Its fair value comes from a detailed projection of a company's future cash flows supported by scenario analysis, not from admiring the strategic pivot in isolation. In that framework, steady execution matters more than headline momentum.

Buybacks support the stock, but they do not replace operating leverage

The £1.3 billion share buyback is a useful signal that management sees value in returning capital while the rebuild continues. But buybacks do not create the same lasting economic change as profitable growth or durable margin expansion.

The distorted forward P/E of 1,209.85 is another reminder that ordinary valuation anchors are less useful here. Whether that reflects temporarily suppressed earnings or a market leaning more on yield and cash flow, the practical point is the same: price has started to do more of the work than fundamentals alone. At this level, BAT likely needs more than one strong quarter to prove the shares are still attractively priced.

What would change the view from expensive to compelling?

At 4,669 GBp, the relevant test is no longer whether the turnaround is real. It is whether the next few results can add enough evidence to justify paying up from here.

Key signals to watch

• Bull-case proof: The planned roll-out of Velo Max in Modern Oral and the anticipated adult-focused Vuse flavours in Vapour need to reinforce management's mid-teens new-category annual revenue growth target with clear demand.
• Upside trigger: A sustained move above the top of the current 52-week range would suggest the market is still underestimating the strength of the transition.
• Downside trigger: A weaker-than-expected recovery in APMEA strong enough to offset U.S. strength would likely cool the narrative.
• Support factor: The £1.3 billion share buyback can help sentiment and per-share math, but it does not prove cleaner unit economics.

On balance, BAT still looks more like a watchlist name than a bargain at this price. The operating story has improved, but the stock does not yet look obviously cheap enough to justify the remaining execution risk.